What is the share price of Gujarat Themis Biosyn Ltd (GUJTHEM) today?
The share price of GUJTHEM as on 11th March 2025 is ₹247.57. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The past returns of Gujarat Themis Biosyn Ltd (GUJTHEM) share are- Past 1 week: 6.24%
- Past 1 month: -9.27%
- Past 3 months: -24.17%
- Past 6 months: -27.96%
- Past 1 year: -5.52%
- Past 3 years: 388.63%
- Past 5 years: 1613.68%
What are the peers or stocks similar to Gujarat Themis Biosyn Ltd (GUJTHEM)?
The peers or stocks similar to Gujarat Themis Biosyn Ltd (GUJTHEM) include:What is the dividend yield % of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The current dividend yield of Gujarat Themis Biosyn Ltd (GUJTHEM) is 1.36.What is the market cap of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹2663.11 Cr as of 11th March 2025.What is the 52 week high and low of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The 52-week high of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹390 and the 52-week low is ₹192.35.What is the PE and PB ratio of Gujarat Themis Biosyn Ltd (GUJTHEM) stock?
The P/E (price-to-earnings) ratio of Gujarat Themis Biosyn Ltd (GUJTHEM) is 45.02. The P/B (price-to-book) ratio is 13.22.Which sector does Gujarat Themis Biosyn Ltd (GUJTHEM) belong to?
Gujarat Themis Biosyn Ltd (GUJTHEM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gujarat Themis Biosyn Ltd (GUJTHEM) shares?
You can directly buy Gujarat Themis Biosyn Ltd (GUJTHEM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gujarat Themis Biosyn Ltd
GUJTHEMGujarat Themis Biosyn Ltd
GUJTHEM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,663 cr, stock is ranked 931
High RiskStock is 3.81x as volatile as Nifty
247.570.41% (-1.03)
247.570.41% (-1.03)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadCurrent price is more than the intrinsic value
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 50.57 | 13.22 | 1.36% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.89 | 5.97 | 0.56% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Gujarat Themis Biosyn Ltd manufactures pharmaceuticals focusing on active pharmaceutical ingredients (APIs) like Rifamycin-S and Lovastatin, primarily through fermentation processes.
Peers
Compare with peersSUNPHARMA
PE Ratio
40.38
1Y Return
1.12%
Buy Reco %
85.29
CIPLA
PE Ratio
28.66
1Y Return
2.75%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
62.75
1Y Return
13.84%
Buy Reco %
68.00
DRREDDY
PE Ratio
16.73
1Y Return
12.31%
Buy Reco %
45.16
MANKIND
PE Ratio
48.73
1Y Return
4.48%
Buy Reco %
80.00
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 32.79 | 36.05 | 38.97 | 43.26 | 86.82 | 93.83 | 118.90 | 154.98 | 174.20 | 157.18 | ||||||||||
Raw Materials | 0.32 | 1.49 | 2.15 | 1.30 | 15.44 | 15.75 | 21.75 | 29.73 | 25.67 | 81.34 | ||||||||||
| Power & Fuel Cost | 17.15 | 17.99 | 19.33 | 20.20 | 22.86 | 16.57 | 21.73 | 26.41 | 26.53 | |||||||||||
| Employee Cost | 4.28 | 4.42 | 4.46 | 5.17 | 6.43 | 7.11 | 7.08 | 7.75 | 10.21 | |||||||||||
| Selling & Administrative Expenses | 0.94 | 0.85 | 1.10 | 1.39 | 1.64 | 1.86 | 2.31 | 6.66 | 8.51 | |||||||||||
| Operating & Other expenses | 3.90 | 4.90 | 5.52 | 5.62 | 6.91 | 8.94 | 3.94 | 4.20 | 20.18 | |||||||||||
EBITDA | 6.20 | 6.40 | 6.41 | 9.58 | 33.54 | 43.60 | 62.09 | 80.23 | 83.10 | 75.84 | ||||||||||
| Depreciation/Amortization | 1.20 | 1.12 | 1.15 | 1.22 | 1.36 | 1.73 | 2.23 | 2.58 | 3.54 | 5.07 | ||||||||||
| PBIT | 5.00 | 5.28 | 5.26 | 8.36 | 32.18 | 41.87 | 59.86 | 77.65 | 79.56 | 70.77 | ||||||||||
| Interest & Other Items | 0.38 | 0.41 | 0.42 | 0.16 | 0.92 | 0.98 | 0.83 | 0.18 | 0.23 | 0.36 | ||||||||||
| PBT | 4.62 | 4.87 | 4.84 | 8.20 | 31.26 | 40.89 | 59.03 | 77.47 | 79.33 | 70.41 | ||||||||||
| Taxes & Other Items | 0.00 | 0.50 | 0.97 | 1.79 | 7.59 | 10.71 | 15.41 | 19.50 | 20.18 | 17.75 | ||||||||||
| Net Income | 4.62 | 4.37 | 3.87 | 6.41 | 23.67 | 30.18 | 43.62 | 57.97 | 59.15 | 52.66 | ||||||||||
| EPS | 0.42 | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.83 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.00 | 1.47 | 0.72 | 3.33 | 0.67 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.37 | 0.14 | 0.61 | 0.14 |
Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd | 45.02 | 13.22 | 1.36% |
| Sun Pharmaceutical Industries Ltd | 40.38 | 5.76 | 0.84% |
| Cipla Ltd | 28.66 | 4.41 | 0.89% |
| Torrent Pharmaceuticals Ltd | 62.75 | 15.16 | 0.91% |
Price Comparison
Compare GUJTHEM with any stock or ETFCompare GUJTHEM with any stock or ETF
GUJTHEM
Shareholdings
Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Shareholding History
Foreign Institutions
Mutual Funds Holding Trend
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
No mutual funds holding trends are available
Top 3 Mutual Funds holding Gujarat Themis Biosyn Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8187% | Percentage of the fund’s portfolio invested in the stock 2.76% | Change in the portfolio weight of the stock over the last 3 months -0.48% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/37 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2121% | Percentage of the fund’s portfolio invested in the stock 0.35% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 36/43 (-12) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 82/103 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateFeb 22, 2024
Interim
Interim | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Feb 22, 2024
Cash Dividend
Ex DateEx DateSep 1, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 1, 2023
Cash Dividend
Ex DateEx DateDec 1, 2022
Interim
Interim | Div/Share: ₹4.40
Dividend/Share
₹4.40
Ex DateEx Date
Dec 1, 2022
Cash Dividend
Ex DateEx DateAug 29, 2022
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Aug 29, 2022
News & Opinions
Articles & Videos
Earnings
Gujarat Themis Biosyn standalone net profit declines 0.31% in the December 2024 quarter
Net profit of Gujarat Themis Biosyn declined 0.31% to Rs 12.97 crore in the quarter ended December 2024 as against Rs 13.01 crore during the previous quarter ended December 2023. Sales rose 1.91% to Rs 39.52 crore in the quarter ended December 2024 as against Rs 38.78 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales39.5238.78 2 OPM %47.7245.56 - PBDT18.9618.67 2 PBT17.4017.69 -2 NP12.9713.01 0 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Gujarat Themis Biosyn to convene board meeting
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required. This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies. Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 15.71% in the September 2024 quarter
Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales34.7239.54 -12 OPM %44.3542.26 - PBDT15.6417.76 -12 PBT14.2016.88 -16 NP10.5712.54 -16 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn schedules board meeting
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Gujarat Themis' Q1 PAT falls over 25% YoY to Rs 13 crore
This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore. Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter. Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24). Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review. As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year. Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O. The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday. In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period. Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Board of Gujarat Themis Biosyn appoints director
The Board of Gujarat Themis Biosyn has approved the appointment of K. G. Ananthakrishnan (DIN: 00019325) as an Additional Independent Director of the Company w.e.f. 26 July 2024. Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn fixes record date for bonus issue
Gujarat Themis Biosyn has fixed 09 August 2024 as record date for issuance of bonus shares. Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 25.28% in the June 2024 quarter
Net profit of Gujarat Themis Biosyn declined 25.28% to Rs 13.24 crore in the quarter ended June 2024 as against Rs 17.72 crore during the previous quarter ended June 2023. Sales declined 21.70% to Rs 38.83 crore in the quarter ended June 2024 as against Rs 49.59 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales38.8349.59 -22 OPM %47.8047.43 - PBDT19.0124.56 -23 PBT17.8623.81 -25 NP13.2417.72 -25 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn schedules board meeting
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 32.13%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0.02% to 0.05%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 55.96%, vs industry avg of 15.27%